Lung repair cells tested in fibrosis trial
Disease control
Completed
This study tested a cell therapy called REGEND001 for people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. 23 adults received either the cell treatment or a placebo to see if it could improve lung function. The therapy uses special lung cells that may…
Phase: PHASE2 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated May 01, 2026 15:59 UTC